A
A
    Global websites
    Local websites
    language header world map

    Innovation

    The Science of Collaboration

    We bring our antibody engineering expertise to pioneering researchers with the intent to advance immunology breakthroughs into differentiated medicines for patients.

    Through collaboration, we have a common purpose and can accelerate discovery processes to bring solutions to patients who need them.

    We know that together we are better.

    Immunology Innovation Program (IIP)

    The Immunology Innovation Program (IIP) is a core business strategy of argenx connecting the specialized insight into disease and target biology of our external scientific and academic collaborators with our unparalleled experience as antibody engineers.

    Co-creation has led to a deep pipeline of highly differentiated product candidates.

    Through the IIP, we hope to together transcend breakthrough research and publications to our ultimate and unifying mission of creating new potential treatment options for patients.

    An Innovation Ecosystem

    "Stepping into these strategic, academic, industry collaborations. This is a wonderful ecosystem that we are creating, by bringing that expertise together.”

    Prof. Bart Lambrecht

    Bringing expertise together

    Case Studies

     Structuring our pipeline growth

    Efgartigimod

    Target:
    FcRn

    Efgartigimod (ARGX-113) was designed as a human IgG1 antibody Fc-fragment, a natural ligand of the neonatal Fc receptor (FcRn). FcRn is known to extend half-life and availability of pathogenic IgG antibodies.

    Efgartigimod has been engineered for increased affinity to FcRn and was built in collaboration with Prof. E. Sally Ward, Ph.D. who is a pioneer of FcRn biology.

    Read more
    ARGX-118

    Target:
    Galectin-10

    ARGX-118 was designed as a highly differentiated antibody against Galectin-10, the protein of Charcot-Leyden crystals, which are implicated as a major contributor to severe asthma and to the persistence of mucus plugs.

    ARGX-118 was built in collaboration with Prof. Bart Lambrecht, M.D., Ph.D. who identified the first novel airway inflammation target in decades.

    Read more
    ARGX-115

    Target:
    GARP

    ARGX-115 (now ABBV-151) was designed as a humanized monoclonal antibody inhibitor of GARP- TGF-β1 and is in development by AbbVie for the treatment of cancer.

    ARGX-115 was built in collaboration with Prof. Sophie Lucas, M.D., Ph.D. who has been a leader in checkpoint biology research since 1985.

    Read more

    Academic Collaborators

    Bern University

    Columbia University

    Institut de Duve

    Leiden University

    Ludwig Cancer Research

    National Jewish Health

    Université Catholique de

    Louvain

    Turin University

    University Of

    Pennsylvania

    NYU School of Medicine

    UT Southwestern

    Flemish Institute for

    Biotechnology

    Utrecht University

    Antibody Engineering

    Innovation and co-creation are at the core of our strategy. We integrate our unique antibody engineering capabilities with the deep disease and target biology expertise of our collaborators. By innovating at the discovery level, we have built a broad pipeline of differentiated potential immunology solutions to offer patients.

    We innovate at both the variable region or V region (where antigens and foreign proteins are recognized) and the constant region or Fc region (where antibodies modulate other cells in the immune system):

     Antibody

    V region

    innovation-1 FC region

    Technology Role

    Suite of Technologies

    Unlock novel and complex targets

    SIMPLE Antibody™ Platform

    SIMPLE Antibody™ is argenx's proprietary platform designed to source V regions from the immune system of "outbred" llamas.

    Modulate immune response

    Three Fc engineering technologies (NHANCE®, ABDEG™ and POTELLIGENT®) are intended to expand the therapeutic index of argenx antibodies.

    Unique suite of technologies enables development of differentiated product candidates against novel targets

    Partnering opportunities

    Deep relationships power the core of our innovation ecosystem, it is a system of co-creation.

    The Immunology Innovation Program is based on mutual respect for the expertise that each partner brings. Our research collaborators bring unique knowledge of disease biology or a disease pathway. argenx can offer antibody engineering capabilities and a path to turn an immunology breakthrough into a clinical development candidate.

    We together with our partners have the potential to create differentiated medicines for patients.

    For more information on partnering opportunities, please contact BD@argenx.com

    lock-image

    argenx respects your privacy
    Personal information is never kept longer than necessary. Personal data is not provided to third parties without permission or used for marketing purposes.